EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence and economics of transvenous ICD lead complications: Implications for tricuspid valve function and interventions

Pamela K Mason, Edward J Schloss, Reece Holbrook, Tanvi Chiddarwar, Jiani Zhou, George H Crossley iD

Journal of Cardiovascular Electrophysiology · 2024

DOI: 10.1111/jce.16385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2024. Verfasst von Pamela K Mason und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Tricuspid Valve, Medicare, Device Removal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Implantable cardioverter‐defibrillators are used globally and are reliable, but complications related to transvenous leads remain a concern. Evidence related to the incidence and costs of those complications is heterogeneous with respect to scope and healthcare system. This analysis aims to create estimates of the incidence and costs of tricuspid valve (TV) complications, lead failures, and lead extractions from a single large real‐world data set. Methods and Results This retrospective longitudinal cohort study used the deidentified Medicare Fee for Service administrative claims database. A total of 116 036 patients with de novo transvenous ICD implant were analyzed. Mean hospital costs were $26 903 for tricuspid valve complications, $20 851 for lead failures, and $22 278 for lead extractions.

Conclusions

Transvenous ICD lead complications incur significant costs to patients, hospitals, and payers when they occur. Advancements in lead technology that reduce these complications could bring significant clinical and economic value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableTricuspid ValveMedicareDevice RemovalDatabases, FactualHospital CostsHumansRetrospective StudiesFemaleMaleIncidenceUnited StatesAgedLongitudinal StudiesAged, 80 and overTreatment OutcomeElectric CountershockAdministrative Claims, HealthcareTime FactorsRisk Factors

Stichwörter der Autor:innen

ICD complicationsimplantable cardioverter defibrillatortricuspid regurgitation

Autor:innen und Institutionen

  • Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Lindner Research Center, The Christ Hospital, Cincinnati, Ohio, USA.
  • Medtronic, Inc., Mounds View, Minnesota, USA.
  • Heart and Vascular Institute, Vanderbilt University, Nashville, Tennessee, USA.

ORCID-Profile: George H Crossley

Förderung

  • Medtronic

Zitieren

APA

Mason, P. K., Schloss, E. J., Holbrook, R., Chiddarwar, T., Zhou, J., & Crossley, G. H. (2024). Incidence and economics of transvenous ICD lead complications: Implications for tricuspid valve function and interventions. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16385

Vancouver

Mason PK, Schloss EJ, Holbrook R, Chiddarwar T, Zhou J, Crossley GH. Incidence and economics of transvenous ICD lead complications: Implications for tricuspid valve function and interventions. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16385

BibTeX
@article{Mason2024,
  author = {Mason, Pamela K and Schloss, Edward J and Holbrook, Reece and Chiddarwar, Tanvi and Zhou, Jiani and Crossley, George H},
  title = {Incidence and economics of transvenous ICD lead complications: Implications for tricuspid valve function and interventions},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2024},
  doi = {10.1111/jce.16385}
}
Kostenlos starten →